

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: **A61K 45/06**

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimer-
swalder Steig 26, 13503 Berlin (DE). **HABEREY, Mar-
tin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIER-
AUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169
Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE
RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular
Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of
Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

AVAILABLE COPY

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendotherial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4

15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high

20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2

25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing

30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or

5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

(a) compounds which inhibit receptor tyrosine kinase activity,

(b) compounds which inhibit ligand binding to receptors,

(c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,

(d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,

(e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

(f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine


kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579. Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/
 antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,
 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell
 targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci. U.S.A94, 8795-
 5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),
 Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example
 molecules of general formula I

15



20

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

R₃ und R₄ a) each independently from each other have the meaning
 of lower alkyl,

9

b) together form a bridge of general partial formula II,




5

m

wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G

20

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

A, B, D, E and T

25

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,

X has the meaning of imino, oxa or thia;

5 Y has the meaning of hydrogene, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherificated or
esterificated hydroxy, nitro, cyano, carboxy, esterificated
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one ore more N-atoms carry
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranil acid derivatives of general formula IV

30



in which

A

has the meaning of group $=NR^2$,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the group


10



15

or A, Z and R^1 together form the group

20



m, n and o

q

 $R_a, R_b, R_c, R_d, R_e, R_f$

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/ or R_a and/ or R_b together with R_c and or R_d or R_e together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R^1 or R^2 ,

has the meaning of group $=NR^9$ or $=N-$,has the meaning of group $-(CH_2)_p$,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C_{1-6} -alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C_{1-6} -alkoxy, C_{1-6} -alkyl or

5

10

X

Y

p

 R^1

15

 R^2


20

 R^3

25

 R^4, R^5, R^6 and R^7

C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group




5 R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V



V,


15

in which


R¹

has the meaning of group


20




14



in which R^5 is chloro, bromo or the group $-OCH_3$,



in which R^7 is $-CH_3$ or chloro,




in which R^8 is -CH₃, fluoro,
chloro or -CF₃

in which R^4 is fluoro,
chloro, bromo, -CF₃,
-N=C, -CH₃, -OCF₃ or
-CH₂OH

in which R^6 is
-CH₃ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts can be used as compound I or II in the inventive pharmaceutical
composition.

These compounds have the same properties as already mentioned above under
compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in
combination.

The above mentioned compounds are also claimed matter within the inventive
combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences
coding for such peptides, which are used for the treatment of angiogeneous
diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59
of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of
main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

- The inventive compositions comprise as compound I or as compound II at least
- 10 one of
- a) compounds which inhibit receptor tyrosine kinase activity,
 - b) compounds which inhibit ligand binding to receptors,
 - c) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 - e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
 - 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
 - f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

25

These compositions are also claimed matter of the present invention.

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites
5 formation in patients. It is also possible to suppress VEGF oedemas.
For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of

30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefore the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, maligneous nephrosclerosis, thrombic microangiopatic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, artherosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 **Example 1**

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

15

20

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are descibed in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx.

200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons

15 when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days.

10

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the
 5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of
 15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of
 20 targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of
 targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex
 via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor
 system by means of the VEGF receptor tyrosine kinase inhibitor (4-
 25 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate
 30 over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I
10 which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
20
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a
25 receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor
30 systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a


14. Pharmaceutical compositions according to claims 1-11 which comprise as

25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as

30 compound I and/ or II at least one small molecule of general formula I

41



I,

in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

R₃ und R₄

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



II,

15


wherein the binding is via the two terminal C- atoms,
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has

5 wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

20 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,


25 whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

30

or double bonds; or an N-oxide of said compound,
wherein one or more N-atoms carry an oxygen atom,
or a salt thereof,

and/or a compound of general formula IV


5



in which

- A has the meaning of group $=NR^2$,
- 10 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,
- Z has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the group


15



or A, Z and R^1 together form the group

20


44



5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R _a and/ or R _b together with R _c and or R _d or R _c together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
15	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
25	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R⁴, R⁵, R⁶ and R⁷


substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R⁵ and R⁶ together form the group



R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts,

and/ or a compound of general formula V




V,

in which


R¹ has the meaning of group

46




in which R⁵ is chloro, bromo or the group -OCH₃,

5



in which R⁷ is -CH₃ or chloro,



in which R^8 is $-CH_3$, fluoro,
chloro or $-CF_3$


in which R^4 is fluoro,
chloro, bromo, $-CF_3$,
 $-N=C$, $-CH_3$, $-OCF_3$ or
 $-CH_2OH$

in which R^6 is
 $-CH_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts.

15

16. Pharmaceutical compositions according to claim 15 which comprise as
compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-
yl]ammonium hydrogen succinate

20

17. Pharmaceutical compositions according to claims 1-16 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium
hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF
conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-
phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-
tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not
identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

- 5 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
- 10 20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
- 20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPMLXX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

```

ttttacagtt ttccttttct tcagagttaa ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt tttttttaa tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccatat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaac gccaaaaaac cataatggtg ccacagggat ggagcaggga agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaacccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttaa 420
aagcaaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctggt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaagggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaacc ccaaacgcga acctaacca agcaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgtaa gagcatagcg acatcacgtg cgttttctta atgtccctgg tggcggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttg aggggagaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtccacagg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatatatt ggcaatttta tattccacag 1260
tcagggtggg ctgcatagac tcatttaatg ttaaaccgca tcaggggcct ctctcccgt 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat cgcagtcctg tctggctgct tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccctc caacaagcat cgcagggcac 1500
tgtctcggg ggtacagacc gtgggtccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgctgttag gccgtgctgt ctggggctcg aggtcttttc tgctgggtgct 1620
cttggacggg cgggtagttc tgctgcagag acaaaagcat tccccttccc ttccgggctg 1680
atthtgggtc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
cagctccttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaa 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct

```

60

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctacccag 60
 acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tcctgtggcc cattagggaa gtgggtgacct cgggagctat ttgcctgttg 180
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
 10 ttgcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtggt gtgcgtatga 480
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540
 cacctcccca tgacatctc catgagcctc ctgatgtagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

<400> 3

20 tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
 tcagccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
 25 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctgcagctct tcagaaacag 180
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tcctgcgcat tgcaggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataaca 420
 30 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctcaactcat 480
 atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 35 <213> Human

<400> 4

40 cccacaacac agggggcctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60
 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
 ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
 ggggtgcgtc ttggccttgc cgtgcctca tccccggct gaggcagcga cacagcagg 240
 gcaccaactc cagcagggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300
 45 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cacgaggtag gggcagggtg 360
 ctgctggca caaaaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
 ggaagcctgc ctctagcaca ctcttgacga gcacactggc gacataggtg cccatcagt 480
 ctccgcggat gcgcaggcga ccattcttctg ccaccgagat cttggccatc tgacgtcta 540
 cggccgccag cgcccgtctc acctgtgggt ccttggccgg cagtggccgc agctccccct 600
 ccttctgccc cagccgtctt tctcgccgag acaggtaaat gacatggccc aggtagacca 660
 50 ggggtgggtgt gctgacgaag aggaactgca gcacccagta gcggtgtgg gagatgggga 720
 aggctgtgtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
 agagcaccgt cagccagatc ttaccacca cggtcgagtg ctccctggacc tggctcagca 900
 acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960
 55 gcacgtcagt gtgtcagcat ggcattcttc tcgttcgccc agcaacaagc ctgcaggag 1020
 gtctgccacg cccgttctac cgcctgcctg ccgggcggcc cagggtggag tggggacgat 1080
 ggcggagtg acgcccgcg

<210> 5
 60 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65 gaggataggg agcctggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

5 aaaaagtgc ttttgaaaat gttgaggttg aaatgatggg aaccaacatt ctttgatttt 120
 agtggggagc ataatagcaa acaccccctt gggttcgcaca tgtacaggaa tgggacccag 180
 ttggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaagtg gggccagggc 240
 ccagacccaa gaggagaggg tggtcgcag acaccccggt atgtcagcat cccccgacct 300
 gccttctggc ggcacctccc ggggtgctgtg ttgagtcagc aggcattggg tgagagcctg 360
 gtatatgctg ggaacagggt gcagggggcca agcgttcctc cttcagcctt gacttggggc 420
 atgcaccccc tctcccccac acacaaacaa gcacttctcc agtatgggtc caggacaggt 480
 gtcccttcag tctctgggtt atgacctcaa gtccacttg ggccctgcag cccagcctgt 540
 10 gttgtaacct ctgcgtcctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600
 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660
 aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720
 ctgggcaggc ttctctgtag aaccccgagg gcttcggccc agaccacagc gtcttgcctt 780
 gagcctagag cagggagtcg cgaacttctg cattcacaga ccacctccac aattgttata 840
 accaaaggcc tctgttctg ttatttcaat taaatcaaca tgctattttg ttttcaactca 900
 15 cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcattgtca cgtgctagtt 960
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

<210> 6

<211> 2313

20 <212> DNA

<213> Human

<400> 6

25 ccagagcagg cctgggtggtg agcagggagc gtgcaccgga cggcgggagc gagcaaatgg 60
 gtctggccat ggagcacgga gggtcctacg ctccggcggtt gggcagctct cggggctgct 120
 ggtattacct gcgtacttct ttccctctcg tctccctcat ccaattcctc atcatcctgg 180
 ggctcgtgct cttcatggtc tatggcaacg tgcacgtgag cacagagtc aacctgcagg 240
 30 ccaccgagcg ccgagccgag ggcctataca gtacgtcctt agggctcacg gcctcccagt 300
 ccaacttgac caaggagctc aacttcacca cccgcgcaaa ggaatgccatc atgcagatgt 360
 ggctgaatgc tcgcccgcag ctggaccgca tcaatgccag cttccgcccag tgccagggtg 420
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcattgctga 540
 35 atcagaaggt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600
 ataaggaaaag cgtgctgctg aacaaacgct tggcggagga acagctgggt gaatgcgtga 660
 aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaagggtgca 720
 agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840
 40 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900
 ggtggaggag cttggcccga gcttcgcgaa ggatatcgaa cgcgtggccc gcgagaactc 960
 agacctccaa cgccagaagc tggaaagccc gcagggcctg cgggcccagtc aggagcgcaa 1020
 acagaaggtg gagaaggagg ctacaggccc ggaggccaag ctccaagctg aatgtctccg 1080
 gcagaccag ctacgctgag aggagaaggc ggtgctgcgg aaggaaacgag acaacctggc 1140
 caaggagctg gaagagaaga agagggaggc ggagcagctc aggatggagc tggccatcag 1200
 45 aaactcagcc ctggacacct gcatcaagac caagtgcag ccgatgatgc cagtgtcaag 1260
 gcccatgggc cctgtcccca acccccagcc catcgaccca gctagcctgg aggagtcca 1320
 gaggaagatc ctggagtccc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380
 ctgaggaggc tccaggcctg aggaccaagg gatggcccga ctccggcggtt tgccgaggat 1440
 gcagggatat gctcacagcg cccgacacaa cccctcccgc cggcccccaa ccaccaggg 1500
 50 ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcaccccg 1560
 cctcacgac cctcaccag agcacacggc cgcgagatg acgtcacgca agcaacggcg 1620
 ctgacgtcac atatcacctg ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680
 tatagcgatg gcgtcgtgca gatgcagcac gtgcacaca gacatgggga acttggcatg 1740
 55 acgtcacacc gagatgcagc aacgacgtca cgggcccagt cgacgtcaca catattaatg 1800
 tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagtg 1860
 tcaacacaca ccatgacaac gacacctata gatattggc caacatcaca tgcacgcatg 1920
 ccctttcaca cacactttct acccaattct cacctagtgt cactgtcccc cgacctggc 1980
 acacgggcca aggtacccac aggatcccat cccctcccgc acagccctgg gccccagcac 2040
 ctcccctcct ccagcttccct ggccctcccag ccacttctc accccagtg cctggacccg 2100
 60 gaggtgagaa caggaagcca ttcacctccg ctcccttgagc gtgagtgttt ccaggacccc 2160
 ctcggggccc tgagccgggg gtgagggtca cctgttgtcg ggaggggagc cactccttct 2220
 ccccaactc ccagccctgc ctgtggccgt ttgaaatgtt ggtggcactt aataaatatt 2280
 agtaaatcct taaaaaaaaa aaaaaaaaaa aaa

65 <210> 7

<211> 389

<212> DNA
<213> Human

<400> 7

5

10

```
gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttgttc 360
tccttttgtg gtgtccagtg ggtaacatc
```

15

<210> 8
<211> 157
<212> DNA
<213> Human

<400> 8

20

```
tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg
```

25

<210> 9
<211> 561
<212> DNA
<213> Human

30

<400> 9

35

40

```
aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttggtg gctgacatac aggtcagcc agcagagaaa gaattctgaa tttcccttgc 120
tgaactgaac tattctgtta catatgggtg acaaatctgt gtgttatttc ttttctacct 180
accatattta aattttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgac 480
ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgcccacat ttctaggaaa a
```

45

<210> 10
<211> 1508
<212> DNA
<213> Human

<400> 10

50

55

60

65

```
cacaaacacg agagactcca cggctctgct gagcaccgcc agcctcctag gctccagcac 60
tcgcagggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtagcag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaactct 240
gagctcaagc caggtgagct taagccactg agcaaggag atttgggcct gcacgcctac 300
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgca cctaccacag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactggt ctaatgatga tgaggacaac 480
tgtgtgacaa acccatgttc ttgcagccag tctcactggt gtacacgatg gtcagccatg 540
gggtgtcatgt cctctttttt gccttgttta tgggtgtacc ttccagccaa ggggtgcctt 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc ccccttagga actttgaaaa accaactatg 720
catcattaat caggaatatt acagtaatga ggattttttt tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgtg gatagctttt 840
gctgttttgcg gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
ctcagctaata ggagctcaaa gtatgagata cagaacttgg tgaccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtag ttgcaaaact 1020
```

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatattttt 1080
 gtatatataca taatatattgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaatat tatactaata tgtgtacat tcggaagaat gtgaatcaat cagtattgtt 1200
 ttagattgta ttttgcccta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 10 ttcattgtata ttgtacagtt acagtataat tcaaccttta ttttctaatt ttttcaacat 1320
 attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaattattt 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440
 gaggggttac agatgcataat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa
 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 15 <400> 11
 20 gggcaggtag tcagggcaca catttcccgt ccattgagac agtagcattc ccggcaccca 60
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtgagaca agtgcccagc 120
 aggatgggtg gccacagctga agcacaggcc gctctgcaat tgcagataag acagccgtga 180
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttg 360
 25 acctcggccg cgaccacgt ggtaccga
 <210> 12
 <211> 981
 <212> DNA
 <213> Human
 30 <400> 12
 35 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggctgagg atcacttgag 120
 ccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgagc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgtgtt ggtcattaaa aacctagtt 240
 taggataaca acatattaat cagggcaaaa tacaaatgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cggttttaca gtgatatcat tatatttcat ttggcagaat 360
 40 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcaoctagtt 420
 taggataaca ggtctgcctg tttgaagatg aaaaaataata cccattttaa atttgccta 480
 ctcaatttcc ttctcagtc cttttaaact tttaaacagc taatcactcc catctacaga 540
 ttaaggtgta tatgccacca aaaccttttg ccacctttaa aatttccttc aaagttttaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 45 cacacagtg agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcatct gcaccagca ccatacctca caggagtcga ctcccacgag ccgcctgtat 960
 50 ataagagttc ttttgatgac g
 <210> 13
 <211> 401
 <212> DNA
 <213> Human
 55 <400> 13
 60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120
 tctctcccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtggctcatc cgattcagag aaatcaagat ctatgacat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360
 65 acttcagcat atttagttgt cattaaaatt aagctgatat t
 <210> 14

<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

```

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacaggtt gagtagagca acaacaacaa aagccttatgc agtcaccttc 120
tttgaaaatg ttaaatataa gtcctattct ctttgtccag ctgggttttag ctagaggtag 180
ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
gaagtaaata tctggggccc atcgcacccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcac ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa ccaggtttaa ttcccactt ttttaagtag gcttagcttt gagtgatttt 420
tggtataaac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaac aatggtgcca tatgtccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacag ctcaaattga gtagtaacca agcttttctg cccaggaagt acaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720
attcaataaa cattagccaa gctaagtgtc caagccactg tgccaggat taacaatata 780
acaacaataa aagacacagt ccttcctctc aagggtgttc gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
gcctatgttc tcagatatcc tggttaggtc aggagtggga acccaaaatc aattctttta 960
acaacacta aaggtgattc taacacaggc ggtgtgagga cc

```

25 <210> 15
 <211> 280
 <212> DNA
 <213> Human

30 <400> 15

```

cgagggtgggc caccggtgtc tgggtctgaga tttttaaatg aggattacat taccctatct 60
ataatattcc tattctaatc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
aaacattatt agaacaacac tgcctaatac cttataagac taaaaaaatc accaagatga 180
aactgtatta tgactctcaa tttttaaaaa tgtagtggtt tgtagtggtt 240
caatcttaac tatttccacct gcccgggcgg ccgctcgagg

```

40 <210> 16
 <211> 2041
 <212> DNA
 <213> Human

<400> 16

```

ccccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagagggtta gcattttttta ggtaaaaata tggttgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aatTTTgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
caggtagcata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaatttttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
ataaaaacaa gcaactgagt ttttctcttg aagtataagg gtctaataaa aaataaaaga 660
tagatatttg ttatagtctg acattttaac agtcatagta ttagacgttt cgtgaccagt 720
gcatttttga ctctctcagg atcaaaaata gagctcgcca actgtattaa atcctcctcc 780
acccctccca ccagttgggtc cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gagggccggg gctcgagcat tcaactcttg 900
ttcctgtaaa tatagtttat tgtcttttgg tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggt tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaatgaag taaatgtcac tctactgtca ttaaataaaa accatttctt 1140
ttgacatttc cttattttcc aaatcctggt caaaaactgc actgggacta tctctcccta 1200
gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctggtgtgtc atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320

```

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
	catcagtgccc	tgaagggttt	aatttttttag	caagggttctc	actaagatca	gtgaagtcaa	1440
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
5	ccaaaaccag	tggccagtga	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
	tcatatgaaa	atctcaggag	agtaagaata	aggtattcag	gttcctccgt	gatttgcata	1620
	gttttctcag	cattttgcag	agaggcacag	ttttcacaat	aatattgggt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggt	tggtttcacc	1740
	tcccggtttc	tgagggtacat	ctttattaac	aagaatcttg	ttagattcgt	tagggacaga	1800
	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atgggttttt	cattcacaag	1860
10	tgagtcacag	atgaaggcag	ctgttgttgg	attataaact	actggctctt	ctgaaggacc	1920
	gggtacagac	gcttgcatta	gaccaccatc	ttgtatactg	ggtgatgatg	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaaagat	ctgtaaaggc	2040
	t						
15	<210>	17					
	<211>	235					
	<212>	DNA					
	<213>	Human					
20	<400>	17					
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccttc	60
	acctctacaa	ataaaaaatt	aaaaaattag	ccaggtgtgg	cagcgaacaa	ctgtagtctc	120
	agatactcag	gagactgagc	tggaagggat	cacttgagcc	caagaagttc	aaggttacag	180
25	tgggccacga	tcatgtcatt	acactccagc	ttgggtgaca	aatgagact	gtcta	
	<210>	18					
	<211>	2732					
	<212>	DNA					
30	<213>	Human					
	<400>	18					
	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgctggct	60
35	tcatgttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttggtga	tcacattgtg	caaaatggtg	aagcattcaa	acactttgaa	180
	accagattct	agcaggttgg	aaaacattaa	gtcttggttg	cttgccgctt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggtccttttg	gttgcttttt	attaatgagg	agactattgt	300
	gatggcatat	ctcttcacta	tatttaattgc	tttccaggga	gtgttcattt	tcatctttca	360
40	ctgtgctctc	caaaaagaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420
	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgtctgc	tattcctctg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaaacaa	tcagaatctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
	tcaaggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
45	catcttcaag	atttatatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720
	ccatggatac	tctaccgcta	aatggtaatt	ttacaacacag	ctactcgctg	cacaagggtg	780
	actataatga	cagcgtgcaa	gttgtggact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgaca	acaacttacg	gggcagcagc	aagactcaca	900
	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
50	ctattgtggc	agatgcttca	tctttaatgc	acagcgacaa	cccagggtcg	gagctccatc	1020
	acaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080
	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagaggctg	1140
	aagatcacct	acagtccccc	aacagagact	ctctttatac	aagcatgccc	aatcttagag	1200
	actctcccta	tccggagagc	agccctgaca	tggaagaaga	cctctctccc	tccaggagga	1260
55	gtgagaatga	ggacattttac	tataaaaagca	tgccaaatct	tggagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatggtta	tataatcccc	attaacaaag	1380
	aaggggtgat	tccagaagga	gatgttagag	aaggacaaat	gcagctggtt	acaagctttt	1440
	aatcatacag	ctaaggaatt	ccaagggccca	catgagagta	ttaataaata	aagacaccat	1500
	tggcctgacg	cagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtggttctc	1560
60	tggtgtaaaa	aagatgactg	aaccttgcat	ttctgtgaat	ttttataaaa	catacaaaaa	1620
	ctttgtatat	acacagagta	tactaaagtg	aattattttg	tacaaagaaa	agagatgcca	1680
	gccagggtatt	ttaagattct	gctgtgtgtt	agagaaattg	tgaacaaagc	aaaacaaaac	1740
	tttccagcca	ttttactgca	gcagtctgtg	aactaaattt	gtaaatatgg	ctgcaccatt	1800
	tttgtaggcc	tgcattgtat	tatatacaag	acgtaggctt	taaaatcctg	tgggacaaat	1860
65	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcatcag	1920
	tttgacgttc	actgcaaatc	ttttacatta	aggcaaagat	tgaacacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatatattt	ttctatttgc	agggtaaaat	aaatacattt	2100
	gtgtccaact	gaaatataat	tgtcattaaa	ataattttta	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	ggttgcacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcattt	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agttagtctt	2280
	tattactttac	atttaaattt	cttattgcca	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	tgtcacccct	gtttattctt	gaacagaggg	caaaagaggg	actgggcact	tctcacaaac	2460
10	tttctagtga	acaaaaggtg	cctattcttt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
	actcttccat	attccttctg	cctatatatta	gtaattaatt	tattttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gcccatcact	aatatccagt	gtaaagttaa	acacggtttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210> 19						
	<211> 276						
	<212> DNA						
	<213> Human						
20	<400> 19						
	ctccctaagt	gatttttaaa	taaattggat	aaacatatga	tataaagtgg	gtacttttaga	60
	aaccgccttt	gcatattttt	tatgtacaaa	tctttgtata	caattccgat	gttccttata	120
25	tattccctat	atagcaaacc	aaaaccagga	cctccaact	gcatgcctca	agtcctgtg	180
	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gccgcgacca	cgctgg			
	<210> 20						
	<211> 2361						
30	<212> DNA						
	<213> Human						
	<400> 20						
35	attgtaccag	ccttgatgaa	cgtgggccct	gcttcgcttt	tgagggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgtga	ccggaagggt	tctcccaagt	120
	cagagtttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagtggat	gtgcttgctg	240
40	agtggggctc	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
	acacacagac	caaactggag	atgctgttta	agaagaacct	atttgagatg	gcgattaacc	360
	ttgccaaagag	ccagcatctg	gacagtgtatg	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatataatc	cgaaccattg	480
	gaaagttgga	gccatcctac	gtgatccgca	agtttctgga	tgcccagcgc	attcacaacc	540
45	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccaccc	600
	tgctcctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaaagc	cactttgatg	tgagacagc	catcaaggtc	ctccggcagg	720
	ctggctacta	ctcccatgcc	ctgtatctgg	cggagaacca	tgacatcat	gagtggtacc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggaagc	840
50	tgccctttga	gcaggcagag	agcaacatga	agcgtacgg	caagatcctc	atgcaccaca	900
	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcag	cgatagggag	gccccaggct	gcagggccaa	ctctgaggag	ttcatcccca	1020
	tctttgcca	taaccgcgca	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactgggccc	1140
55	acgagaagga	tccacaggtc	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
	gtggctcgctt	ctgcgacgtc	tttgacaagg	ccctggctct	gtgccagatg	cacgacttcc	1260
	aggatgggtg	ccgtttacct	tatgagcagg	ggaagctggt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgttcagtag	cggcaggtca	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	accctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
60	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgcca	cctcttctag	1500
	tggtgcagac	cctggcccac	aactccacag	ccacactctc	cgatcatcagg	gactacctgg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accagagaga	gaccacccgt	atccgccagg	agatccaaga	gctcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgcctt	ggagttgccc	tcagtcact	1740
65	tcctgtgtgg	ccactccttc	caccaacact	gctttgagag	ttactcgga	agtgtatgctg	1800
	actgccccac	ctgcctccct	gaaaaccgga	aggtcatgga	tatgatccgg	gcccaggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

	ctgtgattgc	tgactacttt	ggcagaggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagcctgg	aggctgggct	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
5	agaacagaca	caatgggacc	tgggcgggcg	ttacacagaa	ggctggctga	catgcccagg	2160
	gtccactct	catctaattg	cacagccctc	acaagactaa	agcggaaactt	tttcttttcc	2220
	ctggccttcc	ttaattttta	gtcaagcttg	gcaatccctt	cctctttaac	taggcagggtg	2280
	ttagaatcat	ttccagatta	atggggggga	aggggaacct	caggcaaacc	tcctgaagtt	2340
	ttggaaaaaa	aagctgggtt	c				
10	<210> 21						
	<211> 179						
	<212> DNA						
	<213> Human						
15	<400> 21						
	agggtgtaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattctttta	60
	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
20	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
	<210> 22						
	<211> 905						
	<212> DNA						
	<213> Human						
25	<400> 22						
	tttttttttt	ttctttaacc	gtgtggtctt	tatttcagtg	ccagtgttac	agatacaaca	60
	caaatgttcc	agttagaagg	aattcaaacy	gaatgccaag	gtccaagcca	ggctcaagaa	120
30	ataaaaaggg	aggtttggag	taatagataa	gatgactcca	atactcactc	ttcctaaggg	180
	caaagggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccacccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtggtgggaa	300
	taggggtcatt	aataactatg	aatatactct	ttagaagggtg	accatttttg	actttaaagg	360
	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaaagaat	ggcgagaaaag	420
35	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatata	cttcattgcca	480
	aatctcaaca	aaagctcttt	ttaactccat	ctgtccagtg	tttacaataa	aactcgcaag	540
	gtctgaccag	ttcttggtaa	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaggc	taccaggagc	ctaattgcctc	tttcaaactc	tgggggaacc	agtagaaaaa	660
	ggcaggggctc	cctaattgtcc	attattacat	ttccattccg	aatgccagat	gttaaaagtg	720
40	cctgaagatg	gtaacccagc	tagtgaggaa	taaatacccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaagaagg	ggcaactctt	tgctgcagag	acaaagttag	tgttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccagggaat	900
	gttga						
45	<210> 23						
	<211> 2134						
	<212> DNA						
	<213> Human						
50	<400> 23						
	ggtctcttct	ttcctttttt	tttttccaaa	agtgttcttt	tatttctagt	aacatatatt	60
	gtataaatac	tctattttat	atgcacttcc	acaaaagcga	tataatttta	aagttttttt	120
55	cattagaaat	aaatgtataa	aaataaatat	gttattatag	gcattttatta	ctaactatag	180
	tccttcttgg	aaggaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagtaaca	240
	tattttacta	tatacatatg	gaaaaaatca	tattctcaca	gaagagctga	acagacattc	300
	accaggatac	gactgttggg	ccagctgctg	gagatggacc	tgctaccctc	cagcagcctc	360
	cccaccacaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggacctgt	tctacacacc	420
	tcatttttgg	tccggcggtt	catcctcctt	gtgtgattgt	actgattttc	atgagacaca	480
60	agttacttct	ttacatccat	attcccaaaag	cagggttaca	tggtaggaaa	gaaaggaagt	540
	tggagggtact	aagctcattg	tgtctcctct	agctttttacc	agcatctaatt	gcttcactgc	600
	tttttttcca	ttgtagactt	taatgcactt	gaataaatat	atggagtgtg	tttttctcta	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaaaagagg	agccattttg	720
	gttattttcac	gttgctgagc	ctttctctca	tgttgaaaca	tctgaagttt	taattctcgg	780
65	tagaaataat	gtataaacat	tctctgaaac	catagcagcc	ataaacagtg	ctgggtcaaag	840
	atcctatttg	tactcctttc	tccccccatt	gttagtgagg	taaagtaaaa	cagggtcttag	900

5 taaaaatctca cttttctcct actttttcatt tcccaacccc catgatacta agtattttgat 960
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttggtttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggcttttatta 1080
 tgctatatca ctgctcagag gttaataatc ctactaact atcctatcaa atttgcaact 1140
 ggcagtttac tctgatgatt caactccttt tctatctacc ccataatcc caccttactg 1200
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttcttcactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380
 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 10 ctttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggtctgcaca aggtctgggt ctggctgggt tcacttcctt tgcacactcg gaagcaggct 1560
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgcccacag 1740
 15 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa cacctttgta cataatgtct tgctctaagg 1860
 tggacaaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gttcctggat cccctctggt tccgctgttt cacttcgatg ttggtggctc 1980
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040
 20 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttctttttgg 2100
 agtctatgat gcgatcacia ccagctttta caca

<210> 24

<211> 1626

25 <212> DNA

<213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60
 ttattttgaa tacagacatt ggctccaaat ttctatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gtttaaggctg 180
 tatcattttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240
 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300
 35 gaaaaaggca agacaaatgg cctctgtgac tgaatacttc ggcaaaacta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata tttgtagagc ttgcttagaa tggattacat 420
 ggtagtgatg cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggttttag 540
 aaagctttgt ctaaaaaattt ggcctaggaa tggtaacttc attttcagtt gccaaagggg 600
 40 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattaggta ctatctatga 660
 atgtattttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgtggcag 780
 ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840
 tctggaatgc attagttatg ccttgtagca ttcccagaat ttcaggggca tctgtgggtt 900
 45 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atoctaacta actggctctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 aactaagata tttatctatg aagatataaa tgggtcagag agactttcat ctgtggattg 1200
 50 cgttgtttct tagggttctt agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320
 atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380
 tgtgtttggt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
 55 attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatatatt 1560
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa

<210> 25

60 <211> 1420

<212> DNA

<213> Human

<400> 25

65 gtccagcatt gtttctgctt ctgaaatctg tatatgacac tggtttgtaa tcattatgtc 60

5	ttcattgaaa	tccttgctac	ttctcttcc	cctcaatgaa	agacacgaga	gacaagagcg	120
	acacaagc	aagaaaaacg	agcaaggaag	agtatcttca	ttattctcat	tttctctgag	180
	ttggaacaa	aaacatgaag	gactccaact	agaagacaga	tatttacatt	taaatagatt	240
	agtggaagaa	ctttaagagt	ttccacatat	tagttttcat	tttttgagtc	aagagactgc	300
	tccttgctac	gggagacact	agtagtatat	gtttgtaatg	ttactttaaa	attatctttt	360
10	tattttataa	ggcccataaa	tactgggttaa	actctgttaa	aagtgggcct	tctatcttgg	420
	atggtttcac	tgccatcagc	catgctgata	tattagaaat	ggcatcccta	tctacttact	480
	ttaatgctta	aaattataca	taaaatgctt	tatttagaaa	acctacatga	tacagtgggtg	540
	tcagccttgc	catgtatcag	tttcacttga	aatttgagac	caattaaatt	tcaactgttt	600
	aggggtggaga	aagaggtact	ggaaaacatg	cagatgagga	tatcttttat	gtgcaacagt	660
15	atcctttgca	tgaggaggaga	gttactcttg	aaaggcaggc	agcttaagt	gacaatgttt	720
	tgtatatagt	tgagaatttt	acgacacttt	taaaaattgt	gtaattgtta	aatgtccagt	780
	tttgctctgt	tttgccctgaa	gttttagtat	ttgttttcta	gggtggacctc	tgaaaaccaa	840
	accagtacct	ggggagggtta	gatgtgtgtt	tcaggccttg	agtgtatgag	tggttttggct	900
	tgtattttcc	tccagagatt	ttgaacttta	ataattgcgt	gtgtgttttt	ttttttttaa	960
20	gtggctttgt	ttttttttct	caagtaaaat	tgtgaacata	tttcctttat	aggggcaggg	1020
	catgagttag	ggagactgaa	gagtattgta	gactgtacat	gtgccttctt	aatgtgtttc	1080
	tcgacacatt	ttttttcagt	aacttgaaaa	ttcaaaagg	acatttggtt	aggttactgt	1140
	acatcaatct	atgcataaat	ggcagcttgt	tttcttgagc	cactgtctaa	attttgtttt	1200
	tatagaaatt	ttttatactg	attggttcat	agatggtcag	ttttgtacac	agactgaaca	1260
25	atacagcact	ttgccaaaaa	tgagtgtagc	attgtttaaa	cattgtgtgt	taacacctgt	1320
	tctttgtaat	tggtgtgtgg	tgcattttgc	actacctgga	gttacagttt	tcaatctgtc	1380
	agtaaataaa	gtgtccttta	acttcaaaaa	aaaaaaaaa			
	<210> 26						
	<211> 689						
30	<212> DNA						
	<213> Human						
	<400> 26						
35	aaacaaacaa	aaaaaaagtt	agtactgtat	atgtaaatac	tagcttttca	atgtgctata	60
	caacaaatta	tagcacatcc	ttcctttttac	tctgtctcac	ctccttttagg	tgagtacttc	120
	cttaaataag	tgctaaacat	acatatacgg	aacttgaaa	ctttgggttag	ccttgcccta	180
	ggtaatcagc	ctagtttaca	ctgtttccag	ggagtgttg	aattactata	aaccattagc	240
	cacttgtctc	tgcaaccattt	atcacaccag	gacagggctc	ctcaacctgg	gcgtactgtc	300
40	catttggggc	caggtgattc	ttccttgcaa	gggctgtcct	gtacctgccc	ggcgggccgc	360
	tcgaagcgtg	gtcgcggccg	aggtactgaa	aggaccaagg	agctctggct	gccctcagga	420
	attccaaatg	accgaaggaa	caaagcttca	gggctctggg	tggtgtctcc	cactattcag	480
	gaggtggctg	gaggtaacgc	agcttcattt	cgctccagtc	tttccagtat	ttaaagtgtg	540
	tgtcaagatg	ctgcattaaa	tcaggcaggt	ctacaaaggc	atcccaagca	tcaaacatgt	600
45	ctgtgatgaa	gtaatcaatg	aaacaccgga	acctccgacc	acctcctgaa	tagtgggaga	660
	cacacccaga	gcctgaagtt	tgctccttgc				
	<210> 27						
	<211> 471						
	<212> DNA						
50	<213> Human						
	<400> 27						
55	tccacgcggc	atgaagtttg	agattggcca	ggccctgtac	ctgggcttca	tctccttcgt	60
	ccctctcgct	cattgggtggc	accctgcttt	gcctgtcctg	ccaggacgag	gcaccctaca	120
	agccctaacc	caggccccgc	ccagggccac	cacgaccact	gcaaacaccg	cacctgccta	180
	ccagccacca	gctgcctaca	aagacaatcg	ggccccctca	gtgacctcgg	ccaccacagc	240
	gggtacaggc	tgaacgacta	cggtgtgagtc	cccacagcct	gcttctcccc	tggtgtgtgt	300
60	tggtgtgtgt	cccggcgggg	ctgtcaatgg	aggcaggggt	tccagcacia	agtttacttc	360
	tgggcaattt	ttgtatccaa	ggaaataatg	tgaatgcgag	gaaatgtctt	tagagcacag	420
	ggacagaggg	ggaaataaga	ggaggagaaa	gctctctata	ccaaagactg	a	
	<210> 28						
	<211> 929						
65	<212> DNA						
	<213> Human						
	<400> 28						

5 ggtgaactca gtgcattggg ccaatggttc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggttttggc tgctgggtggg ctttcccctc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccggga 180
 gattccaccc cagccctggg acaagtctac tgtcatccac atgactgttg gaggcttcct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgcaactca cctacttcca gttgtctggg gaggattacc gctgggtggg 420
 10 gcgatctgtg ctgagtgttg gctccaccgg cctcttcata ttcctctact cagttttcta 480
 ttatgcccgg cgctccaaca tgtctggggc agtacagaca gtagagtctt tcggctactc 540
 cttactcact gggtatgtct tcttcctcat gctgggcacc atctcctttt tttcttccct 600
 aaagtccatc cggatatatct atgttaacct caagatggac tgagtctgt atggcagaac 660
 tattgctgtt ctctcccttt cttcatgccc ttttgaactc tcctaccagc tttctctctg 720
 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780
 15 ccagagaggg cctggaaatt ataaatctct atcacataag gattatatat ttgaactttt 840
 taagttgcct ttagttttgg tcctgatttt tctttttaca attacaaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

20 <210> 29
 <211> 1775
 <212> DNA
 <213> Human

25 <400> 29

25 gaacgtgatg ggaacttttg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaaat gcttcccaaa aaattactca 120
 ttgacaattc aaattgcaact tggctggcgg cagcccgggc ggccctcagt ccgtgtgggg 180
 30 gcccgcgctg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240
 aggataaagc caccgctggg acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tgggtgatgat gaaggcaaag acgtcatcaa tgaaggtgtt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca acttgtagtt 420
 cacaagagagc tggggcagca tgaagaggaa accaaaggca tagaccccggt tgacgaagct 480
 35 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 cccgacacag agaggtatac gcaggtatga caagtacttc atggcctgag tatcgactc 600
 ctccggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcacttcca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 40 cacggtgctg aagcagcgcc agagcactgc cttgggtggac atgccgatca tgctcttctt 840
 cttcttccag aaactgatgt catttttaaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaag aaggtcagcg ccaggaagta taagttggta tctacaaaaa ttcctttcac 960
 ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020
 gtggatccag aagcgagcc gccccagtga gaccttgtcg taggacacgg tgaggggcag 1080
 45 ctccggtggtg gagcggttta tgaccatcag gtccttcacg cggttgtgta gctggctgat 1140
 gaacaggatg ggcaggtaat gcacggtttt cccagctgg atcatcttca tgtaccgatg 1200
 cacatcgga ggcaggagg acccgtaaaa gacaaagtgt tccgccatca cgttcagcgc 1260
 cagccgcggt cgccagtggg acaactggctc atccagggca ctgctcggct tcttctccgc 1320
 ctcgatctgc tgtgtatcag actccccggt gagcaggttg atttcttctg gcttggggac 1380
 50 catgtaggtg gtcagaggac tgaccaggtg cacctgcttc ccgtcgtgcc acggcaggac 1440
 cccagcgtga tggaggaaga tgtaggcata cagcgtccca ttgtttctcg ttttcttttg 1500
 tacagaaaca ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggtcg atgttgttct cagcacccag gtgggacctc gtcgtggtgt acacgetcag 1620
 ctgcagcttg ggccgccgcg ccaggtaggg ctggatgcag ttggcgctgc cggagcacgg 1680
 55 gcgggtgtag acgatgccgt acatgacca gcaggtgtgc accacgtaga ccacgaacac 1740
 gccaccacc aagctggtga aggagctgcg gcccc

60 <210> 30
 <211> 1546
 <212> DNA
 <213> Human

65 <400> 30

65 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaatt 60
 aaggccctgc caggctggga ggggaattgtc cctgcctgct tctggagaaa gaagatattg 120

	acaccatcta	cgggcacccat	ggaactgctt	caagtgacca	ttctttttct	tctgcccagt	180
	atgtgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacacaaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaa	540
	acagaaaatac	caggtagtgt	tctacaacca	gatgcacac	cttctaaaac	tggtacatta	600
	acctcaatac	cagttacaat	tccagaaaa	acctcacagt	ctcaagtaat	aggcactgag	660
10	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccg	720
	gtgggtattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	tttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgcagctgt	gaggaattct	ctccacacct	aggcaataat	960
15	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccgact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcgtt	cctaggaaaa	ggaattttag	1200
	gaggagaatt	tgtgagcagt	gaatctgaca	gcccaggagg	tgggctcgct	gataggcatg	1260
20	actttcctta	atgtttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tggtcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgacagtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacatatata	gtattttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
25	aatactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
	<213>	Human					
30							
	<400>	31					
	cacttgggca	ccccattttt	ctaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
35	aagggaagtg	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
	atagcaaatg	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgtta	cggatatttc	tggttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgttttaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
	cagtgaatac	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
40	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagtataac	480
	ttttaatagc	ttcctcagca	cactatttcc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccatc	ggctctgtaa	aaaggaagtc	tgaatacaga	gcccacaaca	ctaaaattgt	600
	ttttctagct	acaaagtata	gcatcatcaa	cacagacacg	atttggaactc	cctgacaggt	660
45	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
	ccaaaggcct	tatttgtcac	caccgtcccc				
	<210>	32					
	<211>	1620					
	<212>	DNA					
50	<213>	Human					
	<400>	32					
	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	gtgcagccat	tcataagaac	cttggtgccc	cagaaaaatc	tgctcttttt	ggtaccaaa	120
	ctgaggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggtta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
	atgttctggg	ttttttcctt	cttttttagaa	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
60	aaaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcactta	ttccaggaca	420
	cgctggcatt	tggaactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tcacataattt	tcacacaata	acagtccttt	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgccttc	cccttggttt	tcaagtatct	660
65	tggagttgtg	cacaaaaatt	aggtcatgcc	ttcagtgctt	tggtctttta	acctaccctt	720
	tgacaatcag	gtgctaata	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

	gtgttctctc	taggttggaa	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
5	tcgcaaactc	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgcccagaa	1080
	aaatctgtcc	tttttggtag	caaacctgag	gtcttttggg	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactct	tgcaaaactc	gatgatacct	gcttatgtgg	1200
	attcttttcc	acactgcttt	cattttttaag	tataaagact	tagaaaacta	gaataatgct	1260
10	tttacaataa	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaaccctgt	1320
	atttaaacia	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagttattg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaat	gtgttaactta	agggatttat	atatataaat	1560
15	acatatatac	ctttgttaacc	tttatactgt	aaataaaaaa	gttgcttttag	tcaaaaaaaa	1620
	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaagttaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgatc	ggactaaaga	agaaagggct	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	agggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggtatcaca	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcatgg	tttggagccc	660
	cagacaattg	agtctataca	ccttctcaaa	tcaaaaaaat	gtcccttcat	tggtgcactc	720
35	aataagattg	ataggttata	tgatttgaaa	aagagtctgt	actctgatgt	ggctgtactt	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	cttttggtacc	tacctctgca	catactgggt	atggcatggg	aagtctgatc	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgcaca	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcggtt	gaaggaagga	gatacaatca	ttgttcctgg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattccttga	1260
45	aaagacctgg	agaaaacatt	ggctgggtta	ccctcctctg	tggtctataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	ggtttaaaag	agacactaaa	tgctatacaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttttga	agctctactt	1440
	gaatttctga	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
	attttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacgggtgaa	1800
	gcaggtcagg	tgaacacagg	gacacccatg	tgtgtcccaa	gcaaaaattt	tggtgacatc	1860
55	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atggttgcaaa	aaaaggacaa	1920
	gaagtttgtg	taaaaataga	acctatccct	ggtagtcac	ccaaaatgtt	tggaagacat	1980
	tttgaagcta	cagatattct	tgttagtaag	atcagccggc	agtcatttga	tgactcaaaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgttga	gctgaagaaa	2100
	gtatttgaaa	tcatctaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
60	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tggaggaag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggctgc	tgtttttaag	tttgcccttc	2400
	cccaaatttg	gattttttatt	acagatctaa	agctctttcg	attttatact	gattaaatca	2460
	gtactgcagt	atttgattaa	aaaaaaaaaa	gcagattttg	tgattcttgg	gacttttttg	2520
65	acgtaagaaa	tacttcttta	tttatgcata	ttcttccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

5 agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctgttaggct tccatggtta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940
 tgatcggttt agtagagatt ttatacat

<210> 34

<211> 6011

10 <212> DNA

<213> Human

<400> 34

15

20 accggggcgcc ggacgacccg cacatcttat cctccacgcc ccactcgcac tccggagcggg 60
 accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggcc 120
 cggcttgagc cgagcgcagc acccccgcgc ccccgcgcca gaagtttggt tgaaccgggc 180
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240
 ggaactcccc cggcccaagg ctcggtgggt cggggtcgcg cggccgcaga aggggcccggg 300
 tccgccccgc aggggaggcg cccccgggga cccgagaggg gggtagggac cgcgggtgc 360
 25 tgggtgcggc gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tcccggccc 420
 gctgcgagga ggaggcggcg gcggcgaggg aggatgtact tgggtggcggg ggacaggggg 480
 ttggccgggt gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcg 540
 tccggcaccc gggcgctggt ctgcctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
 aaccgcccgg ggagcatcgt gcagggcgtc tgcggctgct gctacacgtg cgcagccag 660
 30 gggaacgaga gctgcggcgg caccttcggg atttacgaa cctgcgaccg ggggtgctg 720
 gtgtcatccc gcccccgcct caatggcgac tcctcaccg agtacgaagc gggcgtttg 780
 gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
 aatccctttg agtttccaag tcaggatatg tgcttttcag ctttaaagag aattgaagaa 960
 35 gagaagccag attgctccaa ggcccgtgtg gaagtccagt tctctccacg ttgtcctgaa 1020
 gattctgttc tgatcgaggg ttatgtcctt cctggggagt gctgtccctt accgagccg 1080
 tgctgtgca accccgagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaaacca 1200
 gttttcggcg tggactgcag gactgtggaa tgcctactg ttcagcagac cgcgtgtccc 1260
 40 ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac tttgccaa 1320
 agatgcaggt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380
 cgcatagtct ctcgtagcga tgggacacct ggaagtgtgt gtgatgtctt tgaatgtgtt 1440
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560
 45 cagtgtgggt agataaactg cgagaggtac tacgtgcccg aaggagagtg ctgcccagtg 1620
 tgtgaagatc cagtgtatcc ttttaataat cccgctgggt gctatgccaa tggcctgatc 1680
 cttgccacag gagaccggtg gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaaccctgt gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860
 50 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920
 cacaatggtt gtccgacctg tcagtgcata aacaccaggg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggg ttccctactg atgccccaaa ctgtgagatc 2040
 tgtgagtgcc gcccgaaggc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
 55 ctctcatgca gtaagatctg cccttgggt ttccagcagg acagtcacgg ctgtcttate 2220
 tgcaagtgca gagaggcctc tgcttcagct gggccaccca tcctgtcggg cacttgtctc 2280
 accgtggatg gtcatcatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgctgtggc 2400
 aacccacca ttcacctg acagtgctgc ccatcatgtg cagatgactt tgtggtgcag 2460
 60 aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtggaa 2520
 ggagaaacgt ggaacattga ctccgtgact cagtgcacct gccacagcgg acgggtgctg 2580
 tgtgagacag aggtgtgccc accgctgctc tgccagaacc cctcacgcac ccaggattcc 2640
 tgtgcccac agtgtacaga tcaacctttt cggccttcc tgtcccga taacagcga 2700
 cctaattact gcaaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
 65 gacgtttgta ccagctgcat ctgcattgat agcgtaatga gctgtttctc tgagtctctg 2820
 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgtgttcc ctactgcata 2880
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgacgggcca	gaccctctgc	3000
	tcgaccgtca	gctgcccccc	tctgcccctgt	gttgagccca	tcaacgtgga	aggaagttgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
5	aaccatcgag	gagaggttga	cctggaggtt	cccctgtggc	ccacgcctag	tgaaaatgat	3180
	atcgtccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtggttcc	cataattata	3300
	tgccctctcta	ttataatagc	attcctatct	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
10	gactgcaaga	aaggaaccag	agtccagggtg	gacagttccc	agagaatgct	aagaattgca	3480
	gaaccagatg	caagattcag	tggtctctac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaatttct	accaaacagt	gtgaagaaag	gcaactagga	tgaggtttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaaat	agaatttgtg	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttacttg	gatgggctct	gtctacagca	3720
	atgtgcagaa	caagcattcc	cacttttctt	caagataact	gaccaagtgt	tttcttagaa	3780
15	ccaaagtgtt	taaagtgtgt	aagatatatt	tgccgtgaag	atagctgtag	agatatttgg	3840
	ggtggggaca	gtgagtttgg	atggggaaag	gggtgggagg	gtgggtgttg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggt	aacataaaag	cagttcagtg	gcccagaggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctgggtgtctg	caaagctcag	gcctgaatga	4020
	gcaggaacaa	aaaaaggcct	tgcgacccag	ctgccataac	caccttagaa	ctaccagacg	4080
20	agcacatcag	aaccttttga	cagccatccc	aggctctaaag	ccacaagttt	cttttctata	4140
	cagtcacaac	tgtagtaggc	agttaggaag	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttattt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
	atgtgagcac	tgtagctttt	tttttttaca	acgtgacagg	aagaggaggg	agagggtgac	4380
25	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tggtgctttg	ttctgttata	4440
	ttgttggttg	ttcatagttt	ttgttgaagc	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgttttg	ggattccttt	tctttattat	atactgattc	tacaaaaatag	aaactacttc	4560
	attttaattg	tatattattc	aagcaccttt	gttgaagctc	aaaaaaaaatg	atgcctcttt	4620
	aaacttttag	aattatagga	gtattttatg	aactatctta	tgcttcaaaa	aacaaaagta	4680
30	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atattatacac	atacaattta	4740
	tgttttcctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgccttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
35	attcctttat	taaaatcttc	ctcattttgga	tttgctttca	gttggttttc	aatttgctca	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcatcact	aatcagctcc	tggtattttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttggtg	tagtatgcct	caaataataac	tgactgtata	ctatagtggg	aacttttcaa	5220
	acagccctta	gcacttttat	actaatatac	ccatttgtgc	attgagtttt	cttttaaaaa	5280
40	tgcttgttgc	gaaagacaca	gataccaggt	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaag	gaacttttcaa	gtattgttgt	aaataacttg	acagaggttg	ctgaacttta	5400
	aaaaaaatta	atttattatt	ataatgacct	aattttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aaggtgttct	agctgtttgc	atcaaaggaa	5520
	aaaaagattt	attatcaagg	ggcaatatatt	ttatcttttc	caaaaataaat	ttgttaatga	5580
45	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	ttgttttttt	5700
	caatcatggc	catattatga	aaataactaac	aggatatagg	acaagggtga	aatttttttt	5760
	ttattatttt	aaagatatga	ttatctctga	gtgctgtatc	tattactctt	ttactttggg	5820
	tctgttgtgt	ctcttgtaaa	agaaaaatat	aatttcctga	agaataaaat	agatatatgg	5880
50	cacttggagt	gcacatagtg	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrgl	agcghllvsl	lgllllpars	gtralvclpc	deskceepn	rpgsivqgvc	60
	gccytcasgg	nescgggtfgi	ygtcdrglrc	virpplngds	lteyeagvce	denwtddqll	120
65	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdmc	lsalkrieee	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpgc	240

5 ccdlyeckpv fgvdertvec ptvqqtacpp dsyetqvrlt adgcctlptr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmdfr mdncrfrcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsnctltrk 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfgf ltdaqnceic ecrprpkkr 540
 piicdkycpl gllknkhgdc icrckkcpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfvge etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsq cpqctdqpfpr pslsrnnsvp nyckndegdi flaaeswkpq vctscicids 780
 viscfesesc svscerpvlr kgqccpycik dtipkvvch fsgkayadee rwdldscthc 840
 yclqggtlcs tvscpplpcv epinvegscc pmcpemyvpe ptnipiekt n hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiic lsiiiaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsvd ckkgrtrvqd ssqrmrlrae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35

<211> 716

<212> DNA

20 <213> Human

<400> 35

25 gcagtagctg gagtgtcctg caggggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctggggccgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtccag agggatcagc cccagaacac accctcctcc cggggacgcc gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 30 ccagaactcg gtcctatattt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgagggaat ctctcgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360
 aaggctcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
 gtcagtgtgg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggt cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 tctggttagt gtcgtaacct ctgtgtgcct cccgttaccc catctgtcca gtgagctcag 600
 35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36

<211> 395

40 <212> DNA

<213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc caccctaaa atacttcaga ggctgaaaa 180
 atgattatta cattggaatc cttagccta tgtgatattt ctttaacttt gcactttcac 240
 gccagtaaa accaaagtca gggttaacca tgtcatttta caaatgtta aaacccta 300
 50 tgcagttcct tttttaaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37

<211> 134

55 <212> DNA

<213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtagctt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggt gagtctccat 120
 aagggaacac gtgt

<210> 38

65 <211> 644

<212> DNA

<213> Human

<400> 38

```

5  aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
   cagtggcgct tgagtgtgtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
   ggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
   ggaatattgg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
   gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
10  ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360
   aggatgttta tgttcagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
   ttgcgaccgg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480
   caagagggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagtctt 540
   tcaaaggctt ctttggaaaa actggaaaga aagcagttaa agcagtttct gtgggtctaa 600
15  gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

```

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

```

25  ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60
   cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
   gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
   tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
   acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
   agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
30  tggctcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
   ttttttgttt ttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
   aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
   taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
35  atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac

```

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

```

45  acaattttta aataactagc aattaatcac agcatatcag gaaaaagtag acagtgaagt 60
   ctggttagtt tttgtaggct cattatggtt agggctgtta agatgtatat aagaacctac 120
   ctatcatgct gtagtatca ctcattccat tttcatgttc catgcatact cgggcatcat 180
   gctaataatg atccttttaa gcactctcaa ggaacaaaaa gggcctttta tttttataaa 240
   ggtaaaaaaa attccccaaa ttttttgcac tgaatgtacc aaagggtgaag ggacattaca 300
   atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
50  acttccctca cagtgccgtg tctaccacta caaggactgt gcatctaagt aataattttt 420
   taagattcac tatatgtgat agtatgatat gcattttattt aaaatgcatt agactctctt 480
   ccatccatca aatactttac aggatggcat ttaatacaga ttttctgtat ttccccact 540
   gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaaac 600
   tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaatgaa 660
   actcagaact atattttctaa gcctgcattt tcaactgatgc ataattttct tagtaattat 720
55  aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
   ttaattttat gagaaggat tcttcatttt aattgctttt gggattactc cacatctttg 840
   tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900
   attggattga catatgggtt gccagcctat ggggtttacag gcattgccc aacatttctt 960
60  tgagatctat atttataagc agccatggaa ttctatttat gggatgttgg caatcttaca 1020
   ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
   gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
   ctgcactaaa ggcacgtact gcagtgtaga gaaatgttct gaaaaagggt tatagaaatc 1200
   tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
65  ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
   tgaaaaaa

```

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5

<400> 41

10	aacagagact	ggcacaggac	ctcttcattg	caggaagatg	gtagtgtagg	caggtaacat	60
	tgagctcttt	tcaaaaaagg	agagctcttc	ttcaagataa	ggaagtggta	gttatgggtg	120
	taacccccgg	ctatcagtcc	ggatggttgc	caccctcct	gctgtaggat	ggaagcagcc	180
	atggagtggtg	agggaggcgc	aataagacac	ccctccacag	agcttgcat	catgggaagc	240
	tggttctacc	tcttcctggc	tcctttgttt	aaaggcctgg	ctgggagcct	tccttttggg	300
	tgtctttctc	ttctccaacc	aacagaaaag	actgctcttc	aaagggtggag	ggctctcatg	360
15	aaacacagct	gccaggagcc	caggcacagg	gctgggggcc	tggaaaaagg	agggcacaca	420
	ggaggaggga	ggagctggta	gggagatgct	ggctttacct	aaggtctcga	aacaaggagg	480
	gcagaatagg	cagaggcctc	tccgtcccag	gcccattttt	gacagatggc	gggacggaaa	540
	tgcaatagac	cagcctgcaa	gaaagacatg	tgttttgatg	acaggcagtg	tggccgggtg	600
	gaacaagcac	aggccttgga	atccaatgga	ctgaatcaga	accctaggcc	tgccatctgt	660
20	cagccgggtg	acctgggtca	attttagcct	ctaaaaagcct	cagtctcctt	atctgcaaaa	720
	tgaggcctgt	gatacctgtt	ttgaagggtt	gctgagaaaa	ttaaagataa	gggtatccaa	780
	aatagtctac	ggcataacca	ccctgaacgt	gcctaatctc	gtaagctaag	cagggtcagg	840
	cctgggttagt	acctggatgg	ggagagtatg	gaaaacatac	ctgcccgcag	ttggagttgg	900
	actctgtctt	aacagtagcg	tggcacacag	aaggcactca	gtaaataactt	gttgaataaa	960
25	tgaagtagcg	atttggtgtg	aaaaaaa				

<210> 42
 <211> 956
 <212> DNA
 <213> Human

30

<400> 42

35	cggacgggtg	ggcggacgcg	tgggtgcagg	agcagggcgg	ctgccgactg	ccccaaccaa	60
	ggaaggagcc	cctgagtcgg	cctgcgcctc	catccatctg	tccggccaga	gccggcatcc	120
	ttgcctgtct	aaagccttaa	ctaagactcc	cgccccgggc	tggccctgtg	cagaccttac	180
	tcaggggatg	tttacctggt	gctcgggaag	ggaggggaag	gggcccggga	gggggcacgg	240
	caggcgtgtg	gcagccacac	gcaggcggcc	agggcgcca	gggacccaaa	gcaggatgac	300
	cacgcacctc	cacgccactg	cctccccoga	atgcatttgg	aaccaaagtc	taaactgagc	360
40	tcgcagcccc	cgcgcctcc	ctccgcctcc	catcccgctt	agcgtctgtg	acagatggac	420
	gcaggccctg	tccagcccc	agtgcgtctg	ttccggtccc	cacagactgc	cccagccaac	480
	gagattgctg	gaaaccaagt	caggccaggt	gggcggaaca	aagggccagg	tgccggcctg	540
	ggggaacgga	tgctccgagg	actggactgt	ttttttcaca	catcgttgcc	gcagcgggtg	600
	gaaggaaagg	cagatgtaaa	tgatgtgttg	gtttacaggg	tatatttttg	ataccttcaa	660
45	tgaattaatt	cagatgtttt	acgcaaggaa	ggacttacc	agtattactg	ctgctgtgct	720
	tttgatctct	gcttaccgtt	caagaggcgt	gtgcaggccg	acagtcgggtg	accccatcac	780
	tcgcaggacc	aagggggcgg	ggactgctgg	ctcacgcccc	gctgtgtcct	ccctcccctc	840
	ccttccttgg	gcagaatgaa	ttcgtatgct	attctgtggc	cgccatctgc	gcagggtggt	900
	ggtattctgt	catttacaca	cgtcgttcta	attaaaaagc	gaattatact	ccaaaa	

50 <210> 43
 <211> 536
 <212> DNA
 <213> Human

55 <400> 43

60	aaataaacac	ttccataaca	ttttgttttc	gaagtctatt	aatgcaatcc	cacttttttc	60
	cccctagttt	ctaaatgtta	aagagagggg	aaaaaaggct	caggatagtt	ttcacctcac	120
	agtgttagct	gtcttttatt	ttactcttgg	aaatagagac	tccattaggg	ttttgacatt	180
	ttgggaaccc	agttttacca	ttgtgtcagt	aaaacaataa	gatagtttga	gagcatatga	240
	tctaaataaa	gacatttgaa	gggttagttt	gaattctaaa	agtaggtaat	agccaaatag	300
	cattctcatc	ccttaacaga	caaaaactta	tttgtcaaaa	gaattagaaa	aggtgaaaat	360
	attttttcca	gatgaaactt	gtgccacttc	caattgacta	atgaaataca	aggagacaga	420
65	ctggaaaaag	tgggttatgc	cacctttaaa	accctttctg	gtaaatatta	tggtagctaa	480
	agggtgggtt	ccccggcacc	tggacctgga	caggtagggg	tccgtgggtta	accagt	

<210> 44
 <211> 1630
 <212> DNA
 <213> Human

5

<400> 44

10	ggggaggggac	gagtatggaa	ccctgaaggt	agcaagtcca	ggcactggcc	tgaccatccg	60
	gctccctggg	caccaagtcc	caggcaggag	cagctgtttt	ccatcccttc	ccagacaagc	120
	tctattttta	tcacaatgac	ctttagagag	gtctcccagg	ccagctcaag	gtgtcccaact	180
	atccccctctg	gaggggaagag	gcaggaaaat	tctccccggg	tccctgtcat	gctactttct	240
	ccatcccagt	tcagactgtc	caggacatct	tatctgcagc	cataagagaa	ttataaggca	300
	gtgatttccc	ttaggcccag	gacttgggcc	tccagctcat	ctgttccttc	tgggcccatt	360
	catggcaggt	tctgggctca	aagctgaact	ggggagagaa	gagatacaga	gctaccatgt	420
15	gactttacct	gattgccctc	agtttggggt	tgcttattgg	gaaagagaga	gacaaagagt	480
	tacttgttac	gggaaatatg	aaaagcatgg	ccaggatgca	tagaggagat	tctagcaggg	540
	gacaggattg	gctcagatga	cccctgaggg	ctcttccagt	cttgaaatgc	attccatgat	600
	attaggaagt	cggggggtggg	tggtggtggt	gggctagtgg	ggtttgaatt	tagggggccga	660
	tgagcttggg	tacgtgagca	gggtgttaag	ttaggggtctg	cctgtatttc	tggtcccctt	720
20	ggaaatgtcc	ccttcttcag	tgtcagacct	cagtcccagt	gtccatatcg	tgcccagaaa	780
	agtagacatt	atcctgcccc	atcccttccc	cagtgcactc	tgacctagct	agtgcctggg	840
	gcccagtgac	ctgggggagc	ctggctgcag	gccctcactg	gttccctaaa	ccttgggtggc	900
	tgtgattcag	gtccccaggg	gggactcagg	gaggaatatg	gctgagttct	gtagtttcca	960
	gagttggctg	gtagagcctt	ctagagggttc	agaatattag	cttcaggatc	agctgggggt	1020
25	atggaattgg	ctgaggatca	aacgtatgta	ggtgaaagga	taccaggatg	ttgtcaaagg	1080
	tgagggacag	tttgggtttg	ggacttacca	gggtgatggt	agatctggaa	cccccaagtg	1140
	aggctggagg	gagttaaggt	cagtatggaa	gatagggttg	ggacagggtg	ctttggaatg	1200
	aaagagtgac	cttagagggc	tccttggggc	tcaggaatgc	tcctgctgct	gtgaagatga	1260
	gaaggtgctc	ttactcagtt	aatgatgagt	gactatatatt	accaaagccc	ctacctgctg	1320
30	ctgggtccct	tgtagcacag	gagactgggg	ctaagggccc	ctcccaggga	agggacacca	1380
	tcaggcctct	ggctgaggca	gtagcataga	ggatccattt	ctacctgcat	ttcccaggag	1440
	actagcagga	ggcagccttg	agaaaccggc	agttcccaag	ccagcgcttg	gctgttctct	1500
	cattgtcact	gccctctccc	caacctctcc	tctaaccac	tagagattgc	ctgtgtcctg	1560
35	cctcttgctt	cttgtagaat	gcagctctgg	ccctcaataa	atgcttctctg	cattcatctg	1620
	caaaaaaaaa						

<210> 45
 <211> 169
 <212> DNA
 <213> Human

40

<400> 45

45	tcttttgctt	ttagcttttt	atttttgtat	taacaggagt	cttattacac	ataggtctga	60
	taaaactggg	ttatgatctt	cagtctgatt	ccagtgtctg	ataactagat	aacgtatgaa	120
	ggaaaaacga	cgacgaacaa	aaaagtaagt	gcttgggaaga	cttagttga		

<210> 46
 <211> 769
 <212> DNA
 <213> Human

50

<400> 46

55	tgcaggtcat	atttactatc	ggcaataaaa	ggaagcaaag	cagtattaag	cagcgggtgga	60
	atttgcgcgt	ttcacttttt	ataaagtgtc	acataaaaatg	tcataatttc	aaatttaaaa	120
	acataactcc	agttcttacc	atgagaacag	catgggtgatc	acgaaggatc	ttcttgaaaa	180
	aaacaaaaac	aaaaacaaaa	aacaatgatc	tcttctgggt	atcacatcaa	atgagatata	240
	aaggtgtact	aggcaatctt	agagatctgg	caacttattt	tatatataag	gcatctgtga	300
60	ccaagagacg	ttatgaatta	aatgtacaaa	tgtattatgt	ataaatgtat	taaatgcaag	360
	cttcatataa	tgacaccaat	gtctctaagt	tgctcagaga	tcttgactgg	ctgtggccct	420
	ggccagctcc	tttctgata	gtctgattct	gccttcatat	ataggcagct	cctgatcatc	480
	catgccagtg	aatgagaaaa	caagcatgga	atatataaac	tttaacatta	aaaaatgttt	540
	tattttgtaa	taaaatcaaa	tttccattg	aaaccttcaa	aaactttgca	gaatgaggtt	600
65	ttgatataatg	tgtacaagta	gtaccttctt	agtgcaagaa	aacatcatta	tttctgtctg	660
	cctgcctttt	tgtttttaaa	aatgaagact	atcattgaaa	caagtttgtc	ttcagtatca	720

ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc

<210> 47
 <211> 2529
 <212> DNA
 <213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60
 gtgaaaatta gtgactggtt aagggtgtgc actgtacata tcatcatttt ctgactgggg 120
 tcaggacctg gtcctagtc acaagggttg caggaggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
 15 ggatggtggg aagggggctc cctggtgggg ccgagccagg agtcccaagt cagctctcct 300
 gccttactta gctcctggca gaggggtgagt ggggacctac gaggttcaaa atcaaattggc 360
 atttggccag cctggcttta ctaacagggtt ccagagtgct ctctgttggt tgagctctcc 420
 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcc ctctccctcc 540
 actagtgggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
 20 ccagaggccc ctgcaacttt gcggatttcc agaagggtgat aaaaagagca ctcttgagt 660
 ggtgccagg aatgttttaa atctatcagg cacactataa agctggtggt ttcttctac 720
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780
 tgaactctgg tgttgacagg taaaaaggag aagagatggg gactgtgaag aggggagggc 840
 ttccctcctc ttccctcaaga tctttgtttc cataaactat gcagtcataa ttgagaaaaa 900
 25 gcaatagatg gggcttccta ccatttgttg gttattgctg gggttagcca ggagcagtgt 960
 ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttggggtct 1020
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tcctacctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140
 ttatgaaact gaaaatcaaa tcaagggtatt gggaagaata atttcccctc gattccacag 1200
 30 gagggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260
 acaaatcctc aggggttgcc tggctggcag tcacatgctt ccctggtttt agcacacata 1320
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatggtgg tcttttgcac 1440
 gcagttgggc tgacctgaca aagccccag tttcctgttg caggttcttg gagaggatgc 1500
 35 attcaagctt ctgcagccta ggggacagg ctgctgttgc agttattact gcctcgagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
 ctccggcagt attctcggt gtatgttctc tggcagagag aggcagatga acatagtttt 1680
 agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 40 tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
 ccagagccaa taaaagatct ttgagctctc ggtgaattca cgaagtgacc ccagctttag 1860
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtg gagggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
 ctctatctga ggagccccc ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
 45 tgaaaatttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100
 tgaaattata ctctgacagt ttctctctt ctgctcttc cctctgcaga gtcaggacct 2160
 gcagaaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaa 2220
 gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggct 2280
 tcgagtcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
 50 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
 ggggtgtcc

<210> 48
 <211> 1553
 <212> DNA
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
 ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacctgac 120
 aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaaagt 180
 65 ctagccaggc ccgttttcca tccctaagta ccattctctc atttggggcc ttctagggtt 240
 ggggccttga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatccca 300
 tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

ccatcaagag ggctatggga gccaaagtga caccgggggat tgaggctaatt tcacctgaac 420
tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttcctcga 480
gacggagtct cgctgtgttg ccagggctgg agtgcagtgg caccgtctcg gctcactgca 540
agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
5 taggtgccaa ccactacgcc tagctaattt ttttttgtat ttttagtaga gacaggggtt 660
caccgtgtta gccaggatgg tctcgtcctg acttttgtat ccgccgcct cggcctccca 720
aagtgtctggg attacaggcg tgagccacca cacttggccc cggcacgtat cttttaagga 780
atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900
cgagcggggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
acttcagtgg tgacactgga tgggtggaagc cagcctttgg ggcaggaaac cagctcagag 1020
aggctaccca gctcagctgc tggcaggagc caggatttta cagccataat gtgtgtaaag 1080
aaaaaacacg tcttgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
ggatgagctt cactcaacgt ggagatgggt gtggactggt ccctgaaaag cgggctcttg 1200
15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
cgaggggagc aggaggcttc tctctagtcc ctttggaggc tttggctgag agaagagtga 1320
gcagggagct gggaaatggc caggcaggga agggagctga agtgattcgg ggctaattgc 1380
tcagatcgat gtatttctct cctgggtctc cggagccct cttgtcaccg ctgctgcctt 1440
gcagggaggc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
20 tacgagaccg ggggtagcgt gatctcctgc ttcctgagc gcctgcacgg cag

<210> 49
<211> 921
<212> DNA
25 <213> Human

<400> 49

ctgtgggtccc agctactcag gaggctgagg cgggaggatt gcttgagccc aggagtggga 60
30 tgttgcaagt agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
gtctcagaaa acaaacacaa aaaagcagaa acgctgaagg ggtcgggtta cgggaaaacc 180
gctgtgcaga acaactgggt actcctacc cagatcagtg gacctgggaa tgaggggttg 240
tcccgggagg cttttctcca agctgttgcc accagaccgg ccattgggaa cctggccaca 300
gaagcctccc ggggagttag ccagagcctg gaccgtgtg ctgatgtgtc tgggggtggag 360
35 ggaggggtgg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420
tgctgtcctg tgtgtgtgcg tgcccctccc ctgcagccgt cgggtggtatc tccctccagc 480
cccttcgcca cctctgagc attgtctgtc cactgagac tgcccagaga cagcagagct 540
ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600
caggtgctaa atgacccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
40 gtcccgtga cctgccccg tggcgtctca cgtgatgcc tgcctctgac attggtgttc 720
actgtagcaa actacattct ggatgggaat ttcatgtac atgtgtggca tgtggaaaat 780
ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtgggtcctt ccagcacgga 840
tactttgacc tcttgccctac aacccttcc ttgggtccga ggctggtagc tttgttccat 900
45 tcagatgggt gggggcgggg g

<210> 50
<211> 338
<212> DNA
50 <213> Human

<400> 50

atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
55 tcccttccag atattacccc atttctctac ttcccatgtg agccaaactt tccaaaaatt 120
catgttctgt cttcatttcc tcattgtcaa cccaccctgt cttagctacc acccctcagt 180
aacgacctag cctgggtaga acaaatgtc agcatgata catactcaat gatccttcgt 240
cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300
gtaagaaact ttctttcttg aattcttggg tctcttgg

60 <210> 51
<211> 1191
<212> DNA
<213> Human

65 <400> 51

5 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccgggggatgg 60
 ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tggttggtct ctgtgccact 120
 cctggaaaat aatgaattgg gtaaggaaca gttaataaga aaatgtgcct tgctaactgt 180
 gcacattaca acaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300
 tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctcctg acaagtcggg 360
 aatttctcta tttctccact ggtgcaaaga gcgattttct cctgcttct cttctgtcac 420
 ccccgctcct ctccccagg aggtccttgg atttatggta gctttggact tgcttccccg 480
 10 tctgactgtc cttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540
 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780
 15 aaaaagctga actgcaaata tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840
 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960
 ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020
 tatatgccat ggaattaaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080
 cttccaatac ctctggccat cagatgactt taaaaggtag aggagtaaaa gtttaagatg 1140
 20 atggggcaaaa gtccagtgtg ttcagttaaag tgctaatacac aagttggagg t

<210> 52

<211> 1200

<212> DNA

25 <213> Human

<400> 52

30 aacagggact ctactctat caacccagg ctggagtccg gtgcgccac cctggctccc 60
 tgcaacctcc gctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180
 cgcctctctg ccaggccggc atcatatact ttaaatactg ccagatgac tttaatacct 240
 aatacaatat atcaggttgg tttaaaaata attgcttttt tattattttt gcatttttgc 300
 35 accaacctta atgctatgta aatagttgtt atactgttg ttaacaacag tatgacaatt 360
 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420
 ttctcagtggt tttcaattcc tccttggttg aatccatgga tgcaaaaccc acagatatga 480
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540
 atatgtagtg aaagttaatg tacagtggaa agagttagtg aaaacataaa catttggaac 600
 tttcaagaaa ggtagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggctc 660
 40 tgctactaat tagtataat ctttgacaaa attacatcac ctttgagctc cagttgcctc 720
 acctgtaaaa tgaaagaact ggatactctc taaggctcact tccagccctg tcattctata 780
 actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaaat 840
 gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900
 45 gaataatcct ttcaattttt taagaattta aatattttta agggtttgac ctattttatt 960
 agagatgggg tctcactctg tcaccagac tggagtacag tggcacaatc atagctcact 1020
 gctgcctcaa attcatgggc tcaagtgate ctccctgcctc tgccctccaga gtactgcga 1080
 ctatgggcat gtgccaccac gcctggctaa catttgtatt gacctattta tttattgtga 1140
 tttatatcct tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

50 <210> 53

<211> 989

<212> DNA

<213> Human

55 <400> 53

60 aagccaccac tcaaaacttc ctatacatTT tcacagcaga gacaagtga catttatttt 60
 tatgcctttc ttcctatgtg tttttcaagt ctttttcaaa acaaggcccc aggactctcc 120
 gattcaatta gtccttgggc tggctgactg tgcaggagtc caggagacct ctacaaatgc 180
 agagtgactc tttaccaaca taaaccttag atacatgcaa aaagcaggac ccttcctcca 240
 ggaatgtgoc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggaaac 300
 cgactgtgat agagtgctt acatgaacat tgctactgtc tttctttttt tttgagacag 360
 gtttcgcttg tgcccaggct gagtgcattg cgtgatctca ctactgcaa ttccacctcc 420
 aggttcaagc attctcctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480
 65 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaac 540
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

5	cgaccggcca	ctactgtctt	tctttgaccc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aattttcaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gtttggcacc	taagagtatg	acaacagcaa	taaaaagtaa	tttcaaagag	780
	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aaatcagtta	840
	ttaatattat	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgct	ctgtcgccca	gcgggagtg	actggcgcaa	960
	gcccggtcca	ccgcaatctc	tgccaccgc				
10	<210>	54					
	<211>	250					
	<212>	DNA					
	<213>	Human					
15	<400>	54					
	catttcccca	ttggtcctga	tgttgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaatca	agtcctcac	atgggctatt	aaaactaggt	120
	agtggtagg	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcaggga	180
20	aaagggcatt	ctttaggaac	tgcatctggt	aaccacacc	ttgatccaag	agctagggaa	240
	acttcagttg						
	<210>	55					
	<211>	2270					
25	<212>	DNA					
	<213>	Human					
	<400>	55					
30	gcgccccga	gcagcgcccg	cgccctccgc	gccttctccg	ccgggacctc	gagcgaaaga	60
	ggcccgcgcg	ccgcccagcc	ctcgctccc	tgccacccg	gcacaccg	ccgccacccc	120
	gaccccgctg	cgcacggcct	gtccgctgca	caccagcttg	ttggcgctct	cgctcgccg	180
	ctcgccccg	gctaactctg	cgcgccacaa	tgagctcccg	catcgccagg	gcgctcgct	240
	tagtcgtcac	ccttctccac	ttgaccaggc	tggcgctctc	cacctgcccc	gctgcctgcc	300
35	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgg	gctggctccg	gacggctgcg	360
	gctgctgtaa	ggctgcgcc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacaccaa	ggggctggaa	tgcaacttcg	gcgccaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aatataactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gcccactgtg	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
40	ttcctctgtg	tccccagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggtg	660
	tcaagtttac	cgggcagtgc	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagga	ccaggacggc	ctccttgcca	aggagctggg	attcgatgcc	tccgaggtgg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggtccc	840
	ctgttttttg	aatggagcct	cgcacccctt	acaaggccag	aaatgtattg		900
45	ttcaaacac	ttcatggtcc	cagtgtctca	agacctgtgg	aactggtatc	tccacacgag	960
	ttaccaatga	caaccctgag	tgccgccttg	tgaagaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	gccagtgtac	agcagcctga	aaaagggcaa	gaaatgcagc	aaagcaaga	1080
	aatccccga	accagtcagg	tttacttacg	ctggatgttt	gagtgtgaag	aaataccggc	1140
	ccaagtactg	cggttcctgc	gtggacggcc	gatgtgcac	gccccagctg	accaggactg	1200
50	tgaagatg	gttccgctgc	gaagatgggg	agacattttc	caagaacgtc	atgatgatcc	1260
	agtctgcaa	atgcaactac	aactgcccgc	atgccaatga	agcagcggtt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caaggagaa	gagtgtcaga	atcagaatca	tggagaaaat	ggcggggggt	1440
	ggtgtgggtg	atgggactca	ttgtagaaag	gaagccttgc	tcattcttga	ggagcattaa	1500
55	ggtatttcga	aactgccaag	ggtgctggtg	cggatggaca	ctaagtcagc	cacgattgga	1560
	gaatactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgttttct	gtttgtaaat	tatttgctaa	gcataatttc	tctaggcttt	1680
	tttctttttg	gggttctaca	gtcgtaaaag	agataataag	attagtttga	cagtttaaa	1740
	cttttattcg	tcctttgaca	aaagtaaatg	ggagggcatt	ccatcccttc	ctgaaggggg	1800
60	acactccatg	agtgtctgtg	agaggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
	ggtgttttaa	gactgaatgt	tttattttatc	aaaatgtagc	ttttggggag	ggaggggaaa	1920
	tgttaactga	gaataatttg	taaatgattt	taattttata	ttcagtga	agattttatt	1980
	tatggaatta	accattta	aaagaaatat	taccctaata	tctgagtgtg	tgccatttcg	2040
	tattttttaga	ggtgctccaa	agtcatttagg	aacaacctag	ctcacgtact	caattattca	2100
65	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
	ttataccttc	agtagagaaa	agtcttttga	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

<210> 56
 <211> 1636
 <212> DNA
 5 <213> Human

<400> 56

```

10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaagggga 60
   agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccccac 120
   cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatgggtcc 180
   tggtttgctt ggtctcaagg acaactgcat gtcaaactga tcccctggcc gttggaggag 240
   cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
   cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
15 agcccgtggc cttcccacc cagcaggaag ctctgggcac gccaccacc ccaagtgcc 420
   gatgtctctt gcctgggtct tgtacggga ctcaacgatg ggcatatcaa gatctgggag 480
   gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
   agcttcacac ccagtggcag tttgattttg gtctccgctg cacgggataa gactcttcgc 600
   atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660
20 gtttactgct gttccatctc ccagactgc agcatgctgt gctctgcagc tggagagaag 720
   tcgggtcttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
   agcagtgttg tctcttgtga cttctcccc gactctgccc tgcttgtcac ggcttcttac 840
   gataccaatg tgattatgtg ggaccctac accggcgaaa ggctgaggtc actccaccac 900
   acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
25 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
   tgggcccttg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080
   acattttttc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
   tggacagctc ctagggtcct gtctcactg aagcacttat gccggaaaag ccttcgaagt 1200
   ttccctaaca cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260
30 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatact 1320
   cctgtcaaag ggagttgctg gaataatggg ccaaactatc ggtcttgcat tgaaatagca 1380
   tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
   tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
   aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35 aagatggtga aggggtggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
   gacctgtgc tgcgtt

```

<210> 57
 <211> 460
 40 <212> DNA
 <213> Human

<400> 57

```

45 ccattgtgtg atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
   gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
   tggaatgagc taaagcagcc gcctggggtg ggaggccgag cccatttgta tgcagcaggg 180
   ggcaggagcc cagcaaggga gcctccattc ccaggactct ggaggagct gagaccatcc 240
   atgcccgcag agccctccct cacaactccat cctgtccagc cctaattgtg caggtgggga 300
50 aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aacccaacca 360
   gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
   ccgagctega attcgtaatc atggtcatag ctgtttcctg

```

<210> 58
 <211> 1049
 55 <212> DNA
 <213> Human

<400> 58

```

60 atctgatcaa gaatacctgc cctggctcact ctgcggatgt ttctgtccac ttgttcacat 60
   tgaggaccaa gatatacttt tttacagagg cacttgttcg gtctaacaca gacacctcca 120
   tgacgacatg ctggctcaca ttttgagttt ctgcagaagt cccctcccca gcctggacta 180
   cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
65 gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
   ggatctacaa tttttagtag tttccattg tgagtctggg tcatactttt actgcttgat 360

```

5 aaaatgtaaa cttcacctag ttcattctt ccaaatecca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggactttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtataca aatccacca ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctggt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctgggt ggtgctggtt aagtgtgggt tgctccttgg tatggaataa 840
 10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccctg cagggccaaa gagcagttgc cctccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcataataa 180
 gttggtcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctggttacc tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccctgtt ttgtctcgaa gggctccaca 660
 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcgaattta gtagtaatat cggccgc